In recent years, ERBB2 has evolved to become an important prognostic biomarker and therapeutic target for breast cancer, and targeted therapies such as HerceptinTM (trastuzumab) and OmnitargTM (pertuzumab) are now available clinically. This evidence concerns the gene ERBB2 and breast carcinoma.